Factor Therapeutics Ltd  

(Public, ASX:FTT)   Watch this stock  
Find more results for ASX:TIS
-0.0010 (-1.43%)
Oct 24 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.07 - 0.07
52 week 0.03 - 0.07
Open 0.07
Vol / Avg. 64,482.00/918,322.00
Mkt cap 50.37M
P/E     -
Div/yield     -
EPS -0.04
Shares 724.33M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '16) 2016
Net profit margin -602.39% -2127.25%
Operating margin -617.72% -2131.93%
EBITD margin - -752.78%
Return on average assets -38.36% -73.37%
Return on average equity -42.01% -80.51%
CDP Score - -


L 19 179 Turbot St
+61-7-33343900 (Phone)
+61-7-33343999 (Fax)

Website links


Factor Therapeutics Limited, formerly Tissue Therapies Limited, is a biotechnology company. The Company's principal activities include the development and commercialization of its intellectual property in wound care. The Company's lead program, VF-001, is a biologic product for wound care. VF-001 can be used in conjunction with standard care compression bandaging in the community setting. VF-001 is a fusion protein between a truncated vitronectin peptide and Insulin-like growth factor 1(IGF-1). The initial indication for VF-001 is for Venous Leg Ulcers (VLUs). The Company also has other programs in early development to address other wound applications, as well as new products in the ocular wound care space. Its pipeline includes VF-002, a viscous product to assess burn potential, particularly mucosal burns from radiation therapy, and VF-003 and VF-004, for growth in eye procedures/use of glaucoma stents, reduction of fibrosis and minimization of negative effects of ocular surgery.

Officers and directors

Nigel Johnson Acting Chief Executive Officer
Zee Upton Chief Scientific Officer
Christian P. Behrenbruch Ph.D. Executive Director
Saskia Jo Company Secretary
Cherrell Hirst Non-Executive Director
Timothy Richard Hughes Non-Executive Director
Robert Ryan Non-Executive Director